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PRELIMINARY AND SHORT REPORTS
TWO CASES OF PREVENTION AND TREATMENT OF "LEPRA REACTION"
BY CORTISONE*
E. C. DEL Pozo AND A. GONZALEZ OCH0&
The "lepra reaction" occurs very often as an undesirable action of several drugs used
in the treatment of the disease, particularly after 4-4'-diamino-diphenyl-sulfone (DDS)
and derivatives. The frequency and seriousness of the lepra reaction in patients treated
with these sulfones has been a considerable limiting factor for its use.
In view of the allergic aspects of the "lepra reaction", it was thought that Cortisone
could be useful for its prevention and treatment.
For a preliminary testing two patients were selected because of the intense and almost
continuous reactions that they presented. The treatment with DDS had been impossible
because even small doses (50 to 100 mg.) had produced strong exacerbation of the symptoms
and all sort of measures for the treatment of the reactions had failed.
One of the patients (J. H.) presented a lepromatous type of leprosy and the other one
(C. 0.) a tuberculous type. Each was suffering from a "lepra reaction" at the beginning
of this study. One day after treatment with 100 mgm. of DDS daily was begun, a marked
exacerbation of the reaction was present. Erythema and infiltration of the skin of the
face, arms and other regions, disseminated nodules of erythema nodosum and fever were
present. One patient (J. H.) had in addition strong articular pains and marked peri-articular
edema of the hands and feet.
Treatment with 100 mg. a day of Cortisone Acetate ("Cortone" Merck) was started
and the DDS therapy was continued. The following day some relief was evident and two
days later both patients were in about the same general condition as they were prior to
the treatment with DDS. At this stage, the doses of Cortisone and DDS were raised to 200
mg. a day. The improvement of all symptoms continued steadily and in two days more the
patients reported marked diminution of many "old" nodules and complete relief of pain.
There was no fever, the erythema nodosum was reduced. Without changing the dose of
DDS, Cortisone was gradually reduced from 200 mg. to 100, 50, 25 mg. a day and finally
stopped. After two days without Cortisone the lepra reaction was present again with
very marked erythema, nodes and edema. Keeping unchanged the dose of DDS, Cortisone
treatment was resumed. Next day the reaction was again markedly reduced and a day later
it had disappeared almost completely.
At this time we stopped both Cortisone and DDS. After six days fever, erythema, nodes
and edema were present. One of them (J. H.) had in addition unbearable pain and very
strong inflammatory edema of both hands.
Cortisone was given again, this time without DDS. On the following day all symptoms
of the reaction were markedly reduced, the body temperature was normal. Two days of
300 mg. of Cortisone were enough to effect a complete disappearance of the reactions. An
attempt was made to find the minimal maintenance dose. For one of the patients it was
about 50mg. but for the other 100mg. a day was required. When Cortisone was discontinued,
lepra reactions appeared again and in two days they were as strong as before the treatment.
All necessary laboratory analysis for detecting undesirable effects of Cortisone were
followed. The two patients showed a good tolerance to the drug.
These results have been so striking and clear cut that we considered this preliminary
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report justified. However we know that several aspects of the problem remain to be eval-
uated before attempting a discussion of the possible practical value of the use of Cortisone
in leprosy. One of them is the influence of Cortisone on the patient resistance to Myco-
bacterium leprae. The theoretical possibility of an unfavorable action similar to that de-
scribed for tuberculosis must be kept in mind. Several related problems are now under
study at these laboratories.
We have learned that similar clinical testings with Cortisone on leprosy are being con-
ducted at the present time at some other research centers, but we have not as yet been able
to find any reports in the literature.
